Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1

• Published in: Antiviral research Vol. 101; pp. 113 - 121
• Main Authors: Grammen, Carolien, Ariën, Kevin K., Venkatraj, Muthusamy, Joossens, Jurgen, Van der Veken, Pieter, Heeres, Jan, Lewi, Paul J., Haenen, Steven, Augustyns, Koen, Vanham, Guido, Augustijns, Patrick, Brouwers, Joachim
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier B.V 01.01.2014; Elsevier
• Subjects: Anti-HIV microbicide; Anti-Infective Agents - chemistry; Anti-Infective Agents - pharmacokinetics; Anti-Infective Agents - toxicity; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Biological and medical sciences; Biopharmaceutical profiling; Disease Transmission, Infectious - prevention & control; Drug Compounding; Drug Stability; Female; HIV Infections - prevention & control; HIV Infections - transmission; HIV-1 - drug effects; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; In vitro toxicity; Infectious diseases; Medical sciences; Permeability; Pharmacology. Drug treatments; Solubility; Vaginal Creams, Foams, and Jellies - chemistry; Vaginal Creams, Foams, and Jellies - pharmacokinetics; Vaginal Creams, Foams, and Jellies - toxicity; Vaginal flux; Vaginal gel formulation; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Vaginal flux; Anti-HIV microbicide; In vitro toxicity; Biopharmaceutical profiling; Vaginal gel formulation; Antiretroviral agent; HIV-1 virus; Toxicity; Non nucleoside compound; Antimicrobial agent; Colloidal gel; Formulation; Reverse transcriptase inhibitor; Female genital system; Development; Antiviral; Drug; Immunopathology; Evaluation; Retroviridae; Flux; Vagina; AIDS; Biopharmaceuticals; Immune deficiency; Lentivirus; In vitro; Infection; Virus; Viral disease; Dosage form; Human immunodeficiency virus
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2013.11.005

•Diaryltriazine anti-HIV microbicide candidates were biopharmaceutically screened.•UAMC01398 was selected as the lead compound based on activity, safety and biopharmaceutical data.•Stable and safe UAMC01398 gel formulations were developed.•Inclusion of SBEβCD in the gel increased the UAMC01398 flux across HEC-1A cell layers.•These in vitro findings will be further investigated in an in vivo macaque PK/PD study. Diaryltriazines (DATAs) constitute a class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are being investigated for use as anti-HIV microbicides. The aim of the present study was (1) to assess the biopharmaceutical properties of the DATA series, (2) to select the lead candidate as vaginal microbicide and (3) to develop and evaluate gel formulations of the lead candidate. First, the vaginal tissue permeation potential of the different DATAs was screened by performing permeability and solubility measurements. To obtain a suitable formulation of the lead microbicide candidate, several hydroxyethylcellulose-based gels were assessed for their cellular toxicity, stability and ability to enable UAMC01398 epithelial permeation. Also, attention was given to appropriate preservative selection. Because of its favourable in vitro activity, safety and biopharmaceutical profile, UAMC01398 was chosen as the lead microbicide candidate among the DATA series. Formulating UAMC01398 as a vaginal gel did not affect its anti-HIV activity. Safe and chemically stable gel formulations of UAMC01398 (0.02%) included a non-solubilizing gel and a gel containing sulfobutyl ether-β-cyclodextrin (SBE-βCD, 5%) as solubilizing excipient. Inclusion of SBE-βCD in the gel formulation resulted in enhanced microbicide flux across HEC-1A epithelial cell layers, to an extent that could not be achieved by simply increasing the dose of UAMC01398. The applied rational (pre)formulation approach resulted in the development of aqueous-based gel formulations that are appropriate for further in vivo investigation of the anti-HIV microbicide potential of the novel NNRTI UAMC01398.